These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27039262)

  • 1. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.
    Prasad A; Rabionet R; Espinet B; Zapata L; Puiggros A; Melero C; Puig A; Sarria-Trujillo Y; Ossowski S; Garcia-Muret MP; Estrach T; Servitje O; Lopez-Lerma I; Gallardo F; Pujol RM; Estivill X
    J Invest Dermatol; 2016 Jul; 136(7):1490-1499. PubMed ID: 27039262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
    Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
    Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
    da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
    Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
    Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
    Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.
    Chevret E; Merlio JP
    J Invest Dermatol; 2016 Jul; 136(7):1319-1324. PubMed ID: 27342034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.
    Andersson E; Eldfors S; Edgren H; Ellonen P; Väkevä L; Ranki A; Mustjoki S
    Exp Dermatol; 2014 May; 23(5):366-8. PubMed ID: 24689486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.
    Karenko L; Hahtola S; Päivinen S; Karhu R; Syrjä S; Kähkönen M; Nedoszytko B; Kytölä S; Zhou Y; Blazevic V; Pesonen M; Nevala H; Nupponen N; Sihto H; Krebs I; Poustka A; Roszkiewicz J; Saksela K; Peterson P; Visakorpi T; Ranki A
    Cancer Res; 2005 Sep; 65(18):8101-10. PubMed ID: 16166283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
    Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
    Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
    Ungewickell A; Bhaduri A; Rios E; Reuter J; Lee CS; Mah A; Zehnder A; Ohgami R; Kulkarni S; Armstrong R; Weng WK; Gratzinger D; Tavallaee M; Rook A; Snyder M; Kim Y; Khavari PA
    Nat Genet; 2015 Sep; 47(9):1056-60. PubMed ID: 26258847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.
    Brito-Babapulle V; Hamoudi R; Matutes E; Watson S; Kaczmarek P; Maljaie H; Catovsky D
    Br J Haematol; 2000 Jul; 110(1):180-7. PubMed ID: 10930996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
    Wang L; Ni X; Covington KR; Yang BY; Shiu J; Zhang X; Xi L; Meng Q; Langridge T; Drummond J; Donehower LA; Doddapaneni H; Muzny DM; Gibbs RA; Wheeler DA; Duvic M
    Nat Genet; 2015 Dec; 47(12):1426-34. PubMed ID: 26551670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sézary syndrome: old enigmas, new targets.
    Nicolay JP; Felcht M; Schledzewski K; Goerdt S; Géraud C
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):256-64. PubMed ID: 26972187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations in Sezary syndrome.
    Iżykowska K; Przybylski GK
    Leuk Lymphoma; 2011 May; 52(5):745-53. PubMed ID: 21323514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome.
    Marks DI; Vonderheid EC; Kurz BW; Bigler RD; Sinha K; Morgan DA; Sukman A; Nowell PC; Haines DS
    Br J Haematol; 1996 Mar; 92(4):890-9. PubMed ID: 8616082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sézary syndrome with a complex, frameshift p53 gene mutation in a Chernobyl survivor.
    Fraser-Andrews EA; McGregor JM; Crook T; Brookes L; Calonje E; Whittaker SJ
    Clin Exp Dermatol; 2001 Nov; 26(8):683-5. PubMed ID: 11722457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
    Su T; Duran GE; Kwang AC; Ramchurren N; Fling SP; Kim YH; Khodadoust MS
    Oncoimmunology; 2022; 11(1):2115197. PubMed ID: 36046812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.